Your end-to-end CDMO partner
for your viral vector projects
We are a pure play CDMO, specialized in development and manufacturing of viral vectors.
From development to market, we provide GMP viral vectors, contributing to the success of our clients’ immunotherapies and gene therapy innovations.
We have been a pioneer in developing and producing viral vectors.
We are grounded in the Mérieux family’s legacy of biology and vaccine expertise since 1897.
As a pure CDMO player, we contribute to the success of your immunotherapy and gene therapy innovations.
By Gaelle Besomi
/ 4 December 2023
Today, Oxford Biomedica announces the signing of a sale and purchase agreement with Institut Mérieux for the acquisition of ABL...
Read More
By Gaelle Besomi
/ 24 October 2023
CDMOs are an efficient alternative to the in-house development process. ABL’s sole focus is on product development and manufacturing, allowing...
Read More
By Gaelle Besomi
/ 19 October 2023
In the highly competitive biotech industry, trust and credibility play a pivotal role in attracting investors and securing funding. A...
Read More
By Gaelle Besomi
/ 5 October 2023
In the ever-evolving realm of biotechnology, the path to success demands precision, clarity, and strategic planning. Let's explore a cornerstone...
Read More
By Gaelle Besomi
/ 21 September 2023
Oxford Biomedica, a leading quality and innovation-led cell and gene therapy Contract Development Manufacturing Organization, and Institut Mérieux announce that...
Read More
By Gaelle Besomi
/ 18 September 2023
Authors: Dr Cristina URECHE (Business Development Manager at ABL Europe) and Guillaume SIRGUE (Head of Biomanufacturing and Process Development Operations...
Read More
By Justine Chabrol
/ 29 August 2023
Author: Guillaume SIRGUE, Head of BioManufacturing and Process Development Operations, ABL, Lyon, France Article published in Chimica Oggi-Chemistry Today (July/August...
Read More
By Justine Chabrol
/ 25 October 2022
Deal offers developers in cell and gene therapy streamlined access to plasmid DNA and viral vector manufacturing in new, flexible...
Read More
By Justine Chabrol
/ 18 October 2022
Process optimization and manufacturing collaboration will advance development of candidates based onImugene’s chimeric pox vaccinia platform CF33 up to later phase...
Read More
By Justine Chabrol
/ 11 July 2022
Manufacturing collaboration will give KaliVir access to ABL’s long- term expertise in smallpox and oncolytic viruses through adherent platform manufacturing Rockville,...
Read More
